KCIA
INTS icon

Kingsbury Capital Investment Advisors’s Intensity Therapeutics INTS Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
496,493
+458,439
+1,205% +$2.15M 1.72% 10
2026
Q1 		$224K Buy
+38,054
New +$311K 0.21% 91

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Kingsbury Capital Investment Advisors's INTS Position: Q2 2026 in Review

Kingsbury Capital Investment Advisors increased its Intensity Therapeutics (INTS) stake by 1,205% in Q2 2026, buying an estimated $2.15M and bringing the position to 496,493 shares worth $2.04M. The position accounts for 1.72% of the portfolio, ranked #10.

Kingsbury Capital Investment Advisors first reported a position in INTS in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Kingsbury Capital Investment Advisors held 496,493 shares of Intensity Therapeutics worth $2.04M as of Q2 2026.
  • Kingsbury Capital Investment Advisors bought 458,439 Intensity Therapeutics shares in Q2 2026, an estimated $2.15M.
  • Intensity Therapeutics made up 1.72% of Kingsbury Capital Investment Advisors's portfolio in Q2 2026, its #10 holding.
  • Kingsbury Capital Investment Advisors first reported a position in Intensity Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2026, filed 25 Aug 2026.